Tiotropium does not affect lower urinary tract functions in COPD patients with benign prostatic hyperplasia

Area of Science:

• Pulmonology and Urology
• Pharmacology

Background:

• Tiotropium is a common COPD treatment, but its use in patients with benign prostatic hyperplasia (BPH) is cautioned due to potential anticholinergic effects on micturition.
• Limited data exist on the quantitative impact of tiotropium on lower urinary tract dysfunction (LUTD) in COPD patients with BPH.

Purpose of the Study:

• To investigate the effects of tiotropium on lower urinary tract functions in male COPD patients diagnosed with BPH.

Main Methods:

• A prospective pilot study involving 25 male COPD patients with BPH.
• Patients received daily tiotropium for 3 months.
• Lower urinary tract functions were assessed using the International Prostate Symptom Score (IPSS), quality of life (QOL) index, uroflowmetry (Q-max, Q-ave, PVR, BVE), and prostate volume at baseline and post-treatment.

Main Results:

• No cases of acute urinary retention were reported.
• Tiotropium did not significantly alter subjective measures (IPSS, QOL) or objective uroflowmetry parameters (Q-max, Q-ave, PVR, BVE).
• No significant changes were observed in time to Q-max or overall flow time.

Conclusions:

• Tiotropium administration did not demonstrate adverse effects on lower urinary tract functions in COPD patients with BPH.
• Findings suggest tiotropium may be safely prescribed for this patient population.
• Further research with larger COPD patient cohorts is recommended to confirm these preliminary results.